Dre Tatiana Katérina GALPERINE

“Our doubts are traitors,  And make us lose the good we oft might win, By fearing to attempt.” – William Shakespeare

Dr Tatiana Katérina Galpérine (MER, Privat-Docent) is a specialist in infectious diseases, she leads a dedicated group focused on the advancement, clinical utilization, and exploration of fecal microbiota transplantation (FMT). Her primary objective is to delve into the development, clinical applications, and research surrounding FMT, a burgeoning field with immense potential for revolutionizing therapeutic approaches to various infectious and gastrointestinal disorders. She is currently on the board of the French Society of infectious diseases.

Dr. Galpérine is a specialist in infectious diseases responsible for the intestinal microbiota transplantation project at CHUV. The center started in 2019. It was created to treat patients with multi-recurrent Clostridioides difficile infections (3rd episode) in accordance with international recommendations. This is currently the only recommended indication for this treatment. Dr. Galpérine is also involved internationally in the field of FMT. In 2023, she was appointed as an external expert by the Council of Europe for the revision of the intestinal microbiota chapter in the Guide to the Quality and Safety of Tissues and Cells for Human Application. She is the vice president of the French Fecal Microbiota Transplantation Group.

Research topics

Fender Trial : Fecal Microbiota Transplantation in Clostridioides Difficile Infection First Episode and First Recurrence (FENDER) - ClinicalTrials.gov Identifier: NCT05266807

The pragmatic therapeutic trial FENDER, conducted in Switzerland, evaluates the efficacy of FMT versus antibiotics alone in the treatment of initial infections and first recurrences of CDI. The aim of our study is to compare the efficacy of FMT (combined with standard treatment: vancomycin or fidaxomicin) compared to standard treatment (vancomycin or fidaxomicin) in patients with a first CDI episode presenting risk factors for recurrence and in patient with a first CDI recurrence.

Novel formulation for fecal microbiota transplantation in collaboration with

In collaboration with the University of Geneva - ISPSO — School of Pharmaceutical Sciences, University of Geneva (Prof. E. Allemann, Dr Rakotonirina), this research project aims at improving the formulation of FMT.

Risk assessment of Dientamoeba fragilis transmission through fecal microbiota transplantation and its consequences in recipients (FMT-fragilis) in collaboration with Pr Nathalie Kappel and Dr Alicia Moreno (APHP, Paris)

The goal of this project is to evaluate the frequency of detecting Dientamoeba fragilis in donors, transplants after freezing, and recipients. This project is part of the streamlining of the donor's microbiological assessment.




Groupe Français de Transplantation de Microbiote Fécal


 Last updated on 29/04/2024 at 14:20